81 – 90 of 103
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Re : Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48-55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
(
- Contribution to journal › Article
-
Mark
Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease : Semi-ecologic, Nationwide, Population-based Study
(
- Contribution to journal › Article
-
Mark
Benefits and Harms of Treatment of Asymptomatic Bacteriuria : A Systematic Review and Meta-analysis by the European Association of Urology Urological Infection Guidelines Panel
2017) In European Urology(
- Contribution to journal › Article
-
Mark
What are the Benefits and Harms of Ureteroscopy Compared with Shock-wave Lithotripsy in the Treatment of Upper Ureteral Stones? A Systematic Review
(
- Contribution to journal › Scientific review
-
Mark
Re: Treatment Duration of Febrile Urinary Tract Infection: A Pragmatic Randomized, Double-blind, Placebo-controlled Non-inferiority Trial in Men and Women
(
- Contribution to journal › Debate/Note/Editorial
- 2016
-
Mark
Re: Risk of malignant melanoma in men with prostate cancer. Nationwide, population-based cohort study
(
- Contribution to journal › Letter
-
Mark
Making Predictive Biomarkers Readily Available
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Adipose-derived Stem Cells Counteract Urethral Stricture Formation in Rats
(
- Contribution to journal › Article
-
Mark
Circulating Tumor Cell Count as an Indicator of Treatment Benefit in Advanced Prostate Cancer
(
- Contribution to journal › Debate/Note/Editorial